Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Atlassian Corporation PLC (TEAM) Price & Performance

Cassava Sciences IncTrade
Atlassian Corporation PLCTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Atlassian Corporation PLC — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while Atlassian Corporation PLC trades at $153.29 (market cap $38.54B). The key difference: Atlassian Corporation PLC is far larger — about 807.1× Cassava Sciences Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNATEAM
Market Cap
$47.75M$38.54B
Sector
HealthTechnology
52-Week High
$4.64$182.36
52-Week Low
$0.87$57.15
Enterprise Value
-$34.93M$38.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Atlassian Corporation PLC

Atlassian Corporation (TEAM) surged 35.31% to $149.07 following a strong Q4 2026 earnings beat, with revenue up 28% year-over-year to $1.77 billion and cloud revenue accelerating to 31%. The stock is trading near its pivot point of $148, with bullish technical signals from moving averages but overbought RSI readings. Analysts maintain a strong buy consensus with a $161.93 price target, citing enterprise deal expansion and AI platform adoption as key growth drivers.

Outlook remains positive due to robust revenue growth and margin improvement, but risks include high valuation multiples (P/S 5.9, EV/EBITDA 178.27) and persistent net losses. Investors should weigh the company's cloud momentum against profitability challenges and macroeconomic uncertainty impacting software demand.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Atlassian Corporation PLC

Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.

Read more on TEAM